Structures by: Saravanan K.
Total: 15
4-[2-(1,3-Dioxoisoindolin-2-yl)-1,3-thiazol-4-yl]benzonitrile
C18H9N3O2S
IUCrData (2016) 1, 7 x161117
a=7.915(7)Å b=12.1641(10)Å c=17.255(14)Å
α=69.51(2)° β=79.50(2)° γ=82.93(3)°
2-[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione
C18H12N2O3S
IUCrData (2016) 1, 7 x161053
a=7.004(9)Å b=14.054(17)Å c=15.275(19)Å
α=90° β=90.368(12)° γ=90°
2-Chloro-<i>N</i>-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]acetamide
C11H8Cl2N2OS
IUCrData (2016) 1, 6 x160903
a=5.0940(12)Å b=14.738(3)Å c=15.703(3)Å
α=90° β=96.932(9)° γ=90°
2-Chloro-<i>N</i>-(4-phenyl-1,3-thiazol-2-yl)acetamide
C11H9ClN2OS
IUCrData (2016) 1, 6 x160879
a=8.0406(9)Å b=9.2313(14)Å c=15.9898(17)Å
α=85.693(19)° β=76.448(19)° γ=87.082(19)°
3-(4-Methoxyphenyl)-4-methyl-<i>N</i>-[4-(4-methylphenyl)-1,3-thiazol-2-yl]benzamide
C25H22N2O2S
IUCrData (2017) 2, 5 x170721
a=9.7840(10)Å b=10.2910(10)Å c=21.58(2)Å
α=90° β=99.528(11)° γ=90°
3-Methoxy-4-{[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methoxy}benzonitrile
C18H15N3O4
Acta Crystallographica Section E (2018) 74, 12 1919-1922
a=6.0847(14)Å b=8.5048(19)Å c=17.286(4)Å
α=102.668(7)° β=90.646(6)° γ=109.813(8)°
<i>N</i>-(4-{[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]methoxy}phenyl)acetamide
C17H14ClN3O3
Acta Crystallographica Section E (2018) 74, 12 1919-1922
a=42.240(10)Å b=10.233(3)Å c=7.496(2)Å
α=90° β=91.016(11)° γ=90°
2-[4(<i>E</i>)-2,6-Bis(4-chlorophenyl)-3-ethylpiperidin-4-ylidene]acetamide
C21H22Cl2N2O
Acta Crystallographica Section E (2015) 71, 11 o832-o833
a=8.3293(2)Å b=12.2924(3)Å c=19.3226(4)Å
α=90° β=90° γ=90°
2-{2,4-Diphenyl-3-azabicyclo[3.3.1]nonan-9-ylidene}acetonitrile
C22H22N2
Acta Crystallographica Section E (2015) 71, 10 o792-o793
a=7.9672(5)Å b=8.3129(5)Å c=13.6069(8)Å
α=89.607(4)° β=81.886(4)° γ=84.469(4)°
1H-imidazole
C18H17FN2O
Acta Crystallographica Section E (2010) 66, 7 o1791
a=8.51320(10)Å b=9.5128(2)Å c=19.2610(3)Å
α=90° β=96.798(2)° γ=90°
1H-imidazole
C17H16N2,H2O
Acta Crystallographica Section E (2010) 66, 9 o2219
a=25.5498(2)Å b=25.5498(2)Å c=9.37920(10)Å
α=90° β=90° γ=90°
1-(3,5-Dimethoxyphenyl)-2-(4-fluorophenyl)-4,5-dimethyl-1<i>H</i>-imidazole
C19H19FN2O2
Acta Crystallographica Section E (2012) 68, 2 o256
a=6.96540(10)Å b=17.8520(3)Å c=13.7121(3)Å
α=90° β=97.833(2)° γ=90°
1-(3,5-Dimethoxyphenyl)-4,5-dimethyl-2-phenyl-1<i>H</i>-imidazole
C19H20N2O2
Acta Crystallographica Section E (2013) 69, 10 o1502
a=8.363(5)Å b=10.267(5)Å c=10.481(5)Å
α=75.043(5)° β=75.789(5)° γ=74.576(5)°
C30H41Cu3N3O15
C30H41Cu3N3O15
Crystal Growth & Design (2009) 9, 10 4461
a=13.5406(14)Å b=7.9202(8)Å c=16.5960(19)Å
α=90.00° β=99.731(3)° γ=90.00°
C20H26CuN2O9
C20H26CuN2O9
Crystal Growth & Design (2009) 9, 10 4461
a=8.3764(12)Å b=22.157(3)Å c=5.6982(8)Å
α=90.00° β=90.00° γ=90.00°